March 2010 April 2010 May 2010 June 2010 July 2010
August 2010
September 2010 October 2010
November 2010
December 2010 January 2011 February 2011 March 2011 April 2011 May 2011 June 2011 July 2011 August 2011 September 2011 October 2011 November 2011 December 2011 January 2012 February 2012 March 2012 April 2012 May 2012 June 2012 July 2012 August 2012 September 2012 October 2012 November 2012 December 2012 January 2013 February 2013 March 2013 April 2013 May 2013 June 2013 July 2013 August 2013 September 2013 October 2013 November 2013 December 2013 January 2014 February 2014 March 2014 April 2014 May 2014 June 2014 July 2014 August 2014 September 2014 October 2014 November 2014 December 2014 January 2015 February 2015 March 2015 April 2015 May 2015 June 2015 July 2015 August 2015 September 2015 October 2015 November 2015 December 2015 January 2016 February 2016 March 2016 April 2016 May 2016 June 2016 July 2016 August 2016 September 2016 October 2016 November 2016 December 2016 January 2017 February 2017 March 2017 April 2017 May 2017 June 2017 July 2017 August 2017 September 2017 October 2017 November 2017 December 2017 January 2018 February 2018 March 2018 April 2018 May 2018 June 2018 July 2018 August 2018 September 2018 October 2018 November 2018 December 2018 January 2019 February 2019 March 2019 April 2019 May 2019 June 2019 July 2019 August 2019 September 2019 October 2019 November 2019 December 2019 January 2020 February 2020 March 2020 April 2020 May 2020 June 2020 July 2020 August 2020 September 2020 October 2020 November 2020 December 2020 January 2021 February 2021 March 2021 April 2021 May 2021 June 2021 July 2021 August 2021 September 2021 October 2021 November 2021 December 2021 January 2022 February 2022 March 2022 April 2022 May 2022 June 2022 July 2022 August 2022 September 2022 October 2022 November 2022 December 2022 January 2023 February 2023 March 2023 April 2023 May 2023 June 2023 July 2023 August 2023 September 2023 October 2023 November 2023 December 2023 January 2024 February 2024 March 2024 April 2024 May 2024 June 2024 July 2024 August 2024 September 2024 October 2024
News Every Day |

Alzheimer’s treatment donanemab is not a ‘miracle drug’ – not providing it on the NHS is the right choice

There was frustration in some corners of the media when it was announced that a new drug to slow the progression of Alzheimer’s was not going to be made available on the NHS.

Alzheimer’s wonder drug blocked on NHS over cost, a Telegraph headline ran. The Daily Mail went with: Alzheimer’s ‘wonder’ drug will be blocked by NHS from TODAY due to cost.

In late August, the UK’s National Institute for Health and Care Excellence (Nice), which provides clinical guidance for the NHS, rejected another Alzheimer’s treatment called lecanemab. The media response at that time was similar.

One million people in the UK have dementia, and this figure is expected to rise to 1.4 million by 2040. We have no drugs that slow the disease progression – so-called “disease-modifying drugs” – for this mind-robbing disease, only drugs to treat symptoms. It is clear that we need new drugs, so has Nice made the wrong decision?

Let’s dig a bit more into the rationale for Nice’s decision.

The “wonder” drug (or “miracle drug”) that some newspapers referred to is donanemab, an antibody that latches onto amyloid plaques in the brain and removes them. These plaques are the hallmarks of Alzheimer’s, but it is not known if they are the cause of Alzheimer’s or a consequence of it. (Some people have an abundance of these plaques but no Alzheimer’s.)

At the end of October, Nice declined to approve this drug for use on the NHS for treating early-stage Alzheimer’s disease. This was despite the UK’s drugs regulator, the Medicines and Healthcare Regulatory Authority (MHRA) approving donanemab.

How can we explain the different decisions of the two public bodies? And which one was right?

We can understand the decisions in the context of the different roles of the MHRA and Nice. Essentially, the MHRA reviews the scientific evidence and decides whether the drug is safe and effective. It aims to assess whether the benefits outweigh the risks. If they do, then the drug is approved for use in the UK.

Nice focuses on developing guidelines to support the adoption of new treatments, while considering value for money for the taxpayer alongside safety and effectiveness.

We don’t know how much donanemab will cost in the UK. In the US, the list price is £25,000 per patient per year. It is thought that about 70,000 people in the UK would be eligible for treatment with donanemab.

These drugs, donanemab and lecanemab, are given by infusion every two or four weeks and there are additional costs related to this and the monitoring needed.

To successfully treat patients in the very early stages of Alzheimer’s, these people first need to be identified. So new specialist diagnostic clinics would need to be created to test and confirm potential underlying disease. This might include genetic tests and lumbar puncture tests (to look for elevated amyloid in spinal fluid).

The drug infusions need to be started in specialist clinics with trained staff and facilities available for routine administration. This will all potentially increase the medication management burden on the patient and any family carer, which already can be difficult.

Nice concluded that donanemab slows the rate of decline in symptoms, but is not a cure. We don’t know enough about the long-term effects or the cost-effectiveness of this treatment. Nice consulted various expert groups on how well donanemab works, and the consensus was that it is modest at best.

The main outcome measurement used in the clinical trial was the integrated Alzheimer’s disease rating scale at 76 weeks. The scale, which measures both cognition and daily functioning, ranges from 0 to 144. A meaningful change is considered to be five points for people with Alzheimer’s who have mild cognitive impairment and nine points for people with Alzheimer’s who have mild dementia.

The change in the scale from the start of the trial to 76 weeks was −10.19 in patients receiving donanemab compared with −13.11 in patients receiving a placebo. This difference of 2.92 is less than what is considered to be a meaningful change for patients. Given this, donanemab is certainly not a “wonder” drug or a “miracle” drug, and describing it as such may give false hope to vulnerable people with dementia and their family carers.

Substantial side-effects

The side-effect burden of donanemab is substantial and like all new drugs, more side-effects may be identified when it is used in day-to-day practice. One particular concern is swelling and bleeding on the brain.

In human trials, brain swelling and bleeds occurred in 37% of patients on donanemab compared with 15% on the placebo. Overall, 13% of patients on donanemab stopped treatment because of the side-effects compared with 4% on placebo. Although the consequences are generally mild, it can lead to serious problems, such as seizures.

Hypersensitivity reactions, including swelling of the lips, face, tongue, throat and other parts of the body and breathing difficulties, are also a risk.

Many families in the UK have been touched by Alzheimer’s and fully understand the need for effective care. For families, one clear need is social care and support. Government after government has identified the need to invest in and reform social care. This, rather than spending money on drugs of questionable benefit, needs to be the priority.

Ian Maidment does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Надежда Петрова

Теннисная школа экс третьей ракетки мира Петровой открылась в Татарстане

Lennox Lewis Has No Doubt How Anthony Joshua vs Daniel Dubois Rematch Goes: “He’ll Go After Him”

Lindsay Hubbard's Baby Shower Details Revealed, Including Which 'Summer House' Co-Stars Attend

Bay Area high school football: Weekend scoreboard, how Top 25 fared

You need the eyes of a movie hero to spot the 5 horror villains lurking near the crime scene in under 90 secs

Ria.city






Read also

More than half of voters expected to cast early ballot: Gallup

Quickhacks Combo guide

Lauren Oakley drops biggest clue yet Amy Dowden WILL be back on Strictly next week after backstage collapse

News, articles, comments, with a minute-by-minute update, now on Today24.pro

News Every Day

Bay Area high school football: Weekend scoreboard, how Top 25 fared

Today24.pro — latest news 24/7. You can add your news instantly now — here


News Every Day

Lennox Lewis Has No Doubt How Anthony Joshua vs Daniel Dubois Rematch Goes: “He’ll Go After Him”



Sports today


Новости тенниса
WTA

Блинкова на отказе Цуренко вышла во 2-й круг турнира WTA 250 в Мериде, где сыграет с Корнеевой



Спорт в России и мире
Москва

Серпуховские гимнастки завоевали 30 медалей на соревнованиях в Москве



All sports news today





Sports in Russia today

Москва

Назначены арбитры на матчи 14-ого тура МИР РПЛ


Новости России

Game News

World's biggest modding site announces new paid mods policies, with caveats—'as long as it isn't to the detriment of the free modding ecosystem'


Russian.city


Москва

Сотрудники московского ОМОН оказали помощь пострадавшей в ДТП пенсионерке (видео)


Губернаторы России
20

РЕАЛЬНАЯ ПРЕМИЯ MUSICBOX возвращается: 20-летие канала в ритме хитов


Как будет работать закон по передаче полиции данных о психически нездоровых людях

Минфин: Лимитов по «Семейной ипотеке» хватит до конца 2024 года

В Мытищах состоялась отчетно-выборная конференция профсоюза жизнеобеспечения

В Мытищах состоялась отчетно-выборная конференция профсоюза жизнеобеспечения


Любимые хиты от Александра Розенбаума в Санкт-Петербурге

Пресс-секретарь Шнурова: Зоя также останется в группе, она никуда не денется

Певица Бьянка станет новой участницей шоу «Звёзды в Джунглях»

Добрынин, Лязгина, Нисида. Каких звезд мы потеряли в октябре 2024-го


Россиянка Шнайдер с победы стартовала на турнире WTA в Гонконге

Париж (ATP). 2-й круг. Рублев сыграет с Серундоло, Алькарас – с Харри, Циципас встретится с Табило, Рууд – с Томпсоном

Теннисная школа экс третьей ракетки мира Петровой открылась в Татарстане

Елена Рыбакина вылетела на Итоговый турнир WTA



Отделение СФР предоставило 11 жителям региона с нарушениями зрения собак-поводырей

Компания «Мария» рассказала о новых решениях для девелопмента на конференции Московского Бизнес-клуба

Санкт-Петербурге сотрудники ОМОН Росгвардии спасли упавшую в реку девушку

Компания «Мария» рассказала о новых решениях для девелопмента на конференции Московского Бизнес-клуба


Собянин: Более 3,4 тыс. тренеров готовят спортсменов в Москве

Компания «Мария» рассказала о новых решениях для девелопмента на конференции Московского Бизнес-клуба

Республиканец Шварценеггер поддержал демократа Харрис на предстоящих выборах

Тульский АКМ уступил "Динамо-Алтай" со счетом 7:3


Еще 2,6 тысячи заявок по ремонту трубопроводов отработали в Подмосковье

Столичная коммунальная техника переведена в зимний режим работы

В организации "Диалог" раскрыли детали создания ассоциации по фактчекингу

Сергунина: эксперты из КНР поучаствуют в московской выставке «ПРОреставрацию»



Путин в России и мире






Персональные новости Russian.city
Parabasis

Спектакль «Волшебная лампа Аладдина»



News Every Day

Lennox Lewis Has No Doubt How Anthony Joshua vs Daniel Dubois Rematch Goes: “He’ll Go After Him”




Friends of Today24

Музыкальные новости

Персональные новости